<DOC>
	<DOCNO>NCT02496572</DOCNO>
	<brief_summary>Multidrug resistant tuberculosis ( MDR TB ) grow problem people access adequate diagnosis treatment . The current recommend treatment regimen MDR TB minimum 20 month duration high toxicity . Scale MDR TB treatment associate high default rate , experience Medecins Sans Frontieres ( MSF ) programme Uzbekistan show current standard treatment greatly limit ability scale meet high rate MDR TB region . Evidence Bangladesh 2010 show 9-month short-course regimen could achieve relapse-free cure rate 88 % . Several country West Africa start implement similar regimen similar outcome . Evidence effectiveness shorten regimen among region high second line drug use resistance still limit . The investigator propose observational study programmatic condition evaluate effectiveness shorten course MDR TB regimen high MDR/extensively drug resistant ( XDR ) TB prevalence high second-line drug resistance set Karakalpakstan , Uzbekistan .</brief_summary>
	<brief_title>Effectiveness Simplified Short Regimen Multidrug Resistant Tuberculosis Uzbekistan</brief_title>
	<detailed_description>A prospective observational study design . The study regimen compose intensive phase least 4 month duration Pyrazinamide ( Z ) + Ethambutol ( E ) + Isoniazid ( H ) + Moxifloxacin ( Mfx ) + Capreomycin ( Kanamycin/Amikacin ) ( Cm/Km/Am ) + Prothionamide ( Pto ) + Clofazimine ( Cfz ) continuation phase oral drug Z-E-Mfx-Pto-Cfz . Patients follow end treatment 12 month treatment completion order evaluate rate relapse . Data record patient 's clinical file electronic database analyze Stata 11.0 . This study result ongoing collaboration MSF Ministry Health Uzbekistan ; result share national health authority , World Health Organization rest scientific community aim influence improve treatment care patient MDR TB .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<criteria>New presumptively diagnose MDR TB patient ( adults child ) XpertÂ® MTB/RIF ( rifampicin ) Hain MTBDR ( Mycobacterium tuberculosis drug resistance ) , confirm Hain MTBDR plus positive culture initial molecular test negative confirm MGIT ( mycobacteria growth indicator tube ) culture/DST initial molecular test negative ; Children ( &lt; 14 yo ) suspect MDR TB without bacteriological confirmation document close contact confirm MDR TB patient ; AND Informed consent participate study sign patient responsible caretaker patient &lt; 16 year old ( per national legislation ) . Only patient history prior treatment second line antiTB drug less one month eligible inclusion . Patients include regardless HIV status . Baseline contraindication medication study regimen medication , benefit regimen outweigh risk judge treat physician ; Severe renal insufficiency estimate creatinine clearance &lt; 30 ml/min baseline ( calculate CockcroftGault formula ) ; Patients extrapulmonary TB ( without involvement lung parenchyma ) Patients document ofloxacin resistance Patients XDR TB ( additional resistance SLD [ second line drug ] kanamycin ( capreomycin ) AND ofloxacin ) ; Patients resistance Km Cm . Critically ill judgement treat physician unlikely survive 1 week ( patient may still commence standard MDR TB treatment accord Karakalpakstan comprehensive TB treatment guideline ) Has one follow risk factor QTc prolongation : A confirmed prolongation QTc interval ( Fridericia formula ) , e.g. , repeat demonstration QTcF ( Fridericia correction ) interval &gt; 500 m screen ECG ( i.e. , retesting reassess eligibility allow use unscheduled visit screen phase )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Tuberculosis , multidrug resistant</keyword>
	<keyword>Short-course regimen</keyword>
	<keyword>Medecins sans Frontieres , MSF</keyword>
	<keyword>Uzbekistan , Ministry Health</keyword>
</DOC>